Neogenomics Inc
NEO
View Detailed Chart
8.620USD
+0.510+6.29%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
1.11BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+6.29%
5 Days
+15.24%
1 Month
+38.81%
6 Months
-12.40%
Year to Date
-47.69%
1 Year
-47.08%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
15
analysts
Hold
Current Rating
9.591
Target Price
+20.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 29.59% year-on-year.
Overvalued
The company’s latest PE is -9.94, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 126.82M shares, decreasing 9.26% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 14.10M shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Ticker SymbolNEO
CompanyNeogenomics Inc
CEOMr. Antony P. Zook
Websitehttps://neogenomics.com/
Related Instruments
+0.36%
+0.58%
+2.53%
+0.38%
+0.60%
+3.74%
+11.56%
+0.82%
+0.38%
+1.78%
+0.68%
-0.41%
+0.13%
+1.84%
-0.55%
+1.36%
-1.72%
+1.65%
+2.18%
0.00%
